Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,575 | -17,520 | N/A | -33,940 | -49,070 |
| Depreciation Amortization | 40 | 61 | N/A | 8,270 | 6,670 |
| Accounts receivable | 239 | -121 | N/A | N/A | N/A |
| Other Working Capital | 471 | 612 | N/A | 620 | -1,510 |
| Other Operating Activity | 16,869 | 4,676 | 0 | -10,200 | 5,470 |
| Operating Cash Flow | $-13,956 | $-12,291 | $N/A | $-35,250 | $-38,440 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -2,480 | -2,030 |
| Net Acquisitions | N/A | N/A | N/A | -1,970 | -6,970 |
| Other Investing Activity | 72 | 43 | 0 | 7,400 | 8,840 |
| Investing Cash Flow | $72 | $43 | $N/A | $2,950 | $-160 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 17,719 | 17,826 | N/A | N/A | N/A |
| Other Financing Activity | -711 | -1,264 | 0 | 26,320 | 44,510 |
| Financing Cash Flow | $17,008 | $16,563 | $N/A | $26,320 | $44,510 |
| Exchange Rate Effect | 312 | -223 | N/A | 510 | -840 |
| Beginning Cash Position | 12,358 | 8,509 | N/A | 11,260 | 6,190 |
| End Cash Position | 15,795 | 12,602 | N/A | 5,800 | 11,260 |
| Net Cash Flow | $3,437 | $4,093 | $N/A | $-5,450 | $5,060 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,956 | -12,291 | N/A | -35,250 | -38,440 |
| Free Cash Flow | -13,956 | -12,291 | 0 | -35,250 | -38,440 |